¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"lymphocyte analysis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • sensitized lymphocyte
    ¹Î°¨È­¸²ÇÁ±¸
  • antigen analysis
    Ç׿øºÐ¼®
  • arterial blood gas analysis
    µ¿¸ÆÇ÷°¡½ººÐ¼®
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®, ¹æ»çÈ­ºÐ¼®
  • age-period cohort analysis
    ¿¬·É±â°£ÄÚȣƮºÐ¼®
  • analysis
    ºÐ¼®
  • birth cohort analysis
    Ãâ»ýÄÚȣƮºÐ¼®
  • clinical decision analysis
    ÀÓ»óÀÇ»ç°áÁ¤ºÐ¼®
  • clonal analysis
    Ŭ·ÐºÐ¼®
  • cluster analysis
    ¹«¸®ºÐ¼®
  • cohort analysis
    ÄÚȣƮºÐ¼®
  • computer-assisted semen analysis
    ÄÄÇ»ÅÍÁ¤¾×°Ë»ç
  • computerized image analysis
    ÄÄÇ»ÅÍ¿µ»óºÐ¼®
  • control analysis
    ÁöµµºÐ¼®
  • cost-benefit analysis
    ºñ¿ëÆíÀͺм®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • thymus-derived lymphocyte
    °¡½¿»ùÀ¯·¡¸²ÇÁ±¸
  • mixed lymphocyte reaction
    ¸²ÇÁ±¸È¥ÇÕ¹è¾ç¹ÝÀÀ
  • mixed lymphocyte culture test
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç°Ë»ç
  • monocyte lymphocyte ratio
    ´ÜÇÙ±¸¸²ÇÁ±¸ºñÀ²
  • primed lymphocyte typing
    ÃÊȸÇ׿øÀÚ±ØÈĸ²ÇÁ±¸Çüº°È­
  • primed lymphocyte-typing test
    °¨ÀÛ¸²ÇÁ±¸Çüº°°Ë»ç
  • analysis
    ºÐ¼®
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®, ¹æ»çÈ­ºÐ¼®
  • age-period cohort analysis
    ¿¬·É±â°£ÄÚȣƮºÐ¼®
  • antigen analysis
    Ç׿øºÐ¼®
  • birth cohort analysis
    Ãâ»ýÄÚȣƮºÐ¼®
  • case analysis
    Áõ·ÊºÐ¼®
  • clinical decision analysis
    ÀÓ»óÀÇ»ç°áÁ¤ºÐ¼®
  • clonal analysis
    Ŭ·ÐºÐ¼®
  • cluster analysis
    ¹«¸®ºÐ¼®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • primed lymphocyte-typing test
    ÃÊȸ°¨ÀÛ ¸²ÇÁ±¸ÀÌ¿ë Çüº°°Ë»ç
  • DNA sequence analysis
    DNA ¼­¿­ºÐ¼®
  • Data analysis
    Á¤º¸ºÐ¼®
  • Decision analysis
    °áÁ¤ºÐ¼®
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®(¡­ÝÂà°), ¹æ»çÈ­(Û¯ÞÒûù)ºÐ¼®.
  • activation analysis
    ¹æ»çÈ­ºÐ¼®, Ȱ¼ºÈ­ºÐ¼®
  • amniotic fluid analysis
    ¾ç¼öºÐ¼®
  • analysis
    ºÐ¼®
  • analysis of variance technique
    ºÐ»ê±â¼úºÐ¼®
  • analysis, antigen
    Ç׿øºÐ¼®
  • frequency analysis
    Á֯ļöºÐ¼®
  • gas analysis
    °¡½ººÐ¼®.
  • gas analysis
    °¡½ººÐ¼®
  • gasometric analysis
    ±âüÁ¤·®ºÐ¼®.
  • gastric analysis
    À§¾×°Ë»ç(¡­ËþÞÛ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lymphocyte
    ¸²ÇÁ±¸
  • lymphocyte activating factor
    ¸²ÇÁ±¸È°¼ºÀÎÀÚ
  • lymphocyte activating factor (LAF)
    ¸²ÇÁ±¸ Ȱ¼ºÈ­ÀÎÀÚ
  • lymphocyte culture, mixed
    È¥ÇÕ ¸²ÇÁ±¸¹è¾ç
  • lymphocyte defined antigen
    ¸²ÇÁ±¸±ÔÁ¤Ç׿ø.
  • lymphocyte development
    ¸²ÇÁ±¸¹ßÀ°
  • lymphocyte dysfunction
    ¸²ÇÁ±¸±â´ÉÀå¾Ö<--ºÎÀü>
  • lymphocyte inhibitory factor (LIF)
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • lymphocyte interaction
    ¸²ÇÁ±¸»óÈ£ÀÛ¿ë.
  • lymphocyte microcytotoxicity assay
    ¸²ÇÁ±¸¼Ò¼¼Æ÷µ¶¼º°Ë»ç
  • lymphocyte production
    ¸²ÇÁ±¸»ý¼º
  • lymphocyte proliferation
    ¸²ÇÁ±¸Áõ½Ä
  • lymphocyte transformation
    ¸²ÇÁ±¸Àüȯ(¡­Ï¹ ï®üµ).
  • lymphocyte, resident
    »óÁÖ¸²ÇÁ±¸
  • lymphocyte-activating determinant
    ¸²ÇÁ±¸È°¼º °áÁ¤±â
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • elution analysis
    ¿ë¸® ºÐ¼® (éÁ×îÝÂà°)
  • end-group analysis
    Á¾´Ü±â ºÐ¼® (ðûÓ®ÐñÝÂà°)
  • fluctuation analysis
    ¿äµ¿ ºÐ¼®(èôÔÑÝÂà°)
  • gravimetric analysis
    ¹«°Ô ºÐ¼®(ÝÂà°)
  • inhibition analysis
    ÀúÇØºÐ¼®(îÁúªÝÂà°)
  • ionic mobility analysis
    À̿ À̵¿µµ(ì¹ÔÑÓø) ºÐ¼®(ÝÂà°)
  • isoelectric analysis
    µîÀüºÐ¼®(Ôõï³ÝÂà°)
  • isotope dilution analysis
    µ¿À§¿ø¼Ò Èñ¼®ºÐ¼®(ÔÒêÈêªáÈýüà·ÝÂà°)
  • isotopic dilution analysis
    µ¿À§¿ø¼Ò Èñ¼®ºÐ¼®(ÔÒêÈêªáÈýüà·ÝÂà°)
  • kinetic analysis
    ¹ÝÀÀ¼ÓµµºÐ¼®(ÚãëëáÜÓøÝÂà°)
  • methylation analysis
    ¸Þƿȭ(ûù)ºÐ¼®(ÝÂà°)
  • mobility shift analysis
    À̵¿µµ(ì¹ÔÑÓø)¿Å±è ºÐ¼®(ÝÂà°)
  • moving boundary analysis
    À̵¿°æ°è ºÐ¼®(ì¹ÔÑÌÑÍ£ÝÂà°)
  • multiple inhibition analysis
    ´ÙÁß(Òýñì)ÀúÇØ ºÐ¼®(îÁúªÝÂà°)
  • nearest-neighbor base frequency analysis
    ÃÖ±ÙÁ¢ ¿°±â ºóµµºÐ¼®(õÌÐÎïÈç¤ÐñÞºÓøÝÂà°)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • urine analysis
    ¿ä°Ë»ç
  • vector analysis
    ¹éÅͺм®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HLA-LD human lymphocyte antigen-lymphocyte defined
LD labor and delivery; laboratory data; labyrinthine defect; lactate dehydrogenase; laser Doppler; lear...
MLC minimum lethal concentration; mixed leukocyte culture; mixed ligand chelate; mixed lymphocyte concen...
PLT pancreatic lymphocytic infiltration; platelet; primed lymphocyte test; primed lymphocyte typing; psi...
ABGA Arterial Blood Gas Analysis
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
BIA Bioimpedance Analysis
BIA Biomolecular Interaction Analysis
BIA Biospecific Interaction Analysis
BESA Brain electric source analysis
CoMFA Comparative Molecular Field Analysis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • atomic absorption analysis
    ¿øÀÚ Èí±¤ ºÐ¼®
  • binding displacement analysis
    °áÇÕ º¯À§ ºÐ¼®
  • bite analysis
    ±³ÇÕ ºÐ¼®
    ±³ÇÕ°£ °ü°è³ª ±× Ç¥½Ã¸¦ ºÐ¼®ÇÏ´Â °Í.
  • case analysis
    Áõ·Ê ºÐ¼®
  • character analysis
    ¼º°Ý ºÐ¼®
  • cluster analysis
    ±ÕÁÖ±º ºÐ¼®
  • computerized image analysis
    ÄÄÇ»ÅÍ ¿µ»ó ºÐ¼®
  • continuous flow blood analysis
    Áö¼Ó¼º À¯µ¿ Ç÷¾× ºÐ¼®
  • dietary analysis
    ½ÄÀÌ ºÐ¼®
  • dynamic mechanical analysis
    µ¿Àû ±â°èÀû ºÐ¼®
  • ego analysis
    ÀÚ¾Æ ºÐ¼®
  • electron beam microporbe analysis
    ÀüÀÚ±¤ ¹Ì¼¼ Žħ ¿ä¼Ò ºÐ¼®, ÀüÀÚ±¤ ¹Ì¼¼ Žħ ºÐ¼®
  • electron microprobe analysis
    ÀüÀÚ ¹Ì¼¼ Žħ
  • elementary analysis
    ¿ø¼Ò ºÐ¼®
    À¯±â È­ÇÕ¹°¿¡ ÇÔÀ¯µÇ¾î ÀÖ´Â ¿ø¼ÒÀÇ Á¾·ù¸¦ °áÁ¤Çϰųª, ºñÀ²À» °áÁ¤ÇÏ´Â ºÐ¼® ¹æ¹ý. ÀüÀÚ¸¦ Á¤¼º ¿ø¼Ò ºÐ¼®, ÈÄÀÚ¸¦ Á¤·® ¿ø¼Ò ºÐ¼®À̶ó°í ÇÑ´Ù. Á¤¼º ¿ø¼Ò ºÐ¼®, Áï ¿ø¼Ò °ËÃâ¹ý¿¡¼­´Â À¯±â È­ÇÕ¹°À» ±¸¼ºÇϰí ÀÖ´Â °¢ ¿ø¼Ò¿¡ µû¶ó ¿©·¯ °¡Áö ¹æ¹ýÀÌ »ç¿ëµÇÁö¸¸, ¸ðµÎ À¯±â È­ÇÕ¹°À» ºÐÇØÇÏ¿© °£´ÜÇÑ ¹«±â È­ÇÕ¹°·Î °ËÃâÇÑ´Ù. Á¤·® ¿ø¼Ò ºÐ¼®, Áï ÇÔÀ¯·®À» °áÁ¤ÇÏ´Â ¹æ¹ý¿¡´Â äÃëÇÏ´Â ½Ã·áÀÇ ¾ç¿¡ µû¶ó¼­ »ó·®¹ý
  • Enlow Analysis
    ¿£·Î¿ì ºÐ¼®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
minor lymphocyte stimulatory antigens Endogenous superantigens responsible for inducing strong proliferative responses in T-cells in mixed lymphocyte reactions (see mixed lymphocyte culture test). They are encoded by mouse mammary tumour viruses that have integrated into the germ line as DNA proviruses (minor lymphocyte stimulatory loci).
(12 Dec 1998)
minor lymphocyte stimulatory loci Genetic loci responsible for the encoding of minor lymphocyte stimulatory antigens. There are at least two unlinked loci (in the mouse) and they appear to be separate from the major histocompatibility complex and minor histocompatibility loci. The mouse mammary tumour virus (see mammary tumour viruses, mouse) has the ability to integrate into these loci. The antigens induce strong T-cell proliferative responses in mixed lymphocyte reactions.
(12 Dec 1998)
mixed lymphocyte culture <investigation> Test to determine whether a patients and donor's white blood cells interact adversely. Often used to determine whether a person would be a suitable bone marrow donor for a particular patient.
(16 Dec 1997)
mixed lymphocyte culture test Measure of histocompatibility at the hl-a locus. Peripheral blood lymphocytes from two individuals are mixed together in tissue culture for several days. Lymphocytes from incompatible individuals will stimulate each other to proliferate significantly (measured by tritiated thymidine uptake) whereas those from compatible individuals will not. In the one-way mlc test, the lymphocytes from one of the individuals are inactivated (usually by treatment with mitomycin c or radiation) thereby allowing only the untreated remaining population of cells to proliferate in response to foreign histocompatibility antigens.
(12 Dec 1998)
mixed lymphocyte reaction <haematology, immunology, investigation> Reaction of mitogenesis produced in T lymphocytes when allogeneic (i.e. Mixed) lymphocytes are brought together, provided they are mismatched in histocompatibility loci. Once used as a test for possible graft compatibility in human grafting. Now known that a negative reaction is a poor predictor of graft acceptance.
(18 Nov 1997)
pre-B lymphocyte An early B-lymphoid type cell that is recognised by immunofluorescence as a u-positive, L-chain-negative bone marrow cell.
(05 Mar 2000)
cytotoxic t-lymphocyte A type of CD8 or, less often, CD4 lymphocyte that kills diseased cells infected by a specific virus or other intracellular microbe. CTLs interact with MHC class I receptors (see Major Histocompatibility Complex). On infected cells and have the prime role in cellmediated immunity (see). Cytovene:
See: Ganciclovir.
(09 Oct 1997)
cytotoxic T lymphocyte-specific serine protease <enzyme> Structural sequence given in first source
Registry number: EC 3.4.21.-
Synonym: cytotoxic t lymphocyte-specific serine protease ccp I, cytotoxic t lymphocyte specific serine protease ccp II, mast cell protease type II
(26 Jun 1999)
helper t lymphocyte <haematology, immunology> A type of white blood cell produced by the thymus gland whose presence is necessary for normal levels of antibodies to be produced by B lymphocytes, both in the body (in vivo) and in experimental situations (in vitro).
(09 Oct 1997)
human lymphocyte antigen A system designation for the gene products of at least four linked loci (A, B, C, and D) and a member of subloci on the sixth human chromosome which have been shown to have a strong influence on human allotransplantation, transfusions in refractory patients, and certain disease associations; more than 50 alleles are recognised, most of which are at loci HLA-A and HLA-B; autosomal dominant inheritance.
(05 Mar 2000)
subacute lymphocyte thyroiditis A subacute variant of Hashimoto's thyroiditis.
(05 Mar 2000)
t4 helper lymphocyte A specific type of lymphocyte, derived from the thymus gland, that plays an important role in cellular immunity. T4 lymphocytes (CD4 cells) are decreased (absolute counts less than 200) in patients with AIDS resulting in compromised immune function.
(27 Sep 1997)
thymus derived lymphocyte <haematology, immunology> A class of lymphocytes, so called because they are derived from the thymus and have been through thymic processing. Involved primarily in controlling cell-mediated immune reactions and in the control of B-cell development. The T-cells coordinate the immune system by secreting lymphokine hormones.
There are 3 fundamentally different types of t cells : helper, killer, and suppressor. Each has many subdivisions. T-cells are also called t lymphocytes.
They bear T-cell antigen receptors (CD3) and lack Fc or C3b receptors. Major T-cell subsets are CD4 (mainly helper cells) and CD8 (mostly cytotoxic or suppressor T-cells). Uncontrolled proliferation of this type of cell gives rise to T-cell leukaemia/lymphoma.
(21 Jun 1999)
T lymphocyte <haematology, immunology> A class of lymphocytes, so called because they are derived from the thymus and have been through thymic processing. Involved primarily in controlling cell-mediated immune reactions and in the control of B-cell development, aiding B lymphocytes in making antibodies, and helping in the recognition and rejection of foreign tissues. T lymphocytes are also important in the bodys defense against cancer.
They bear T-cell antigen receptors (CD3) and lack Fc or C3b receptors. Major T-cell subsets are CD4 (mainly helper cells) and CD8 (mostly cytotoxic or suppressor T-cells). Uncontrolled proliferation of this type of cell gives rise to T-cell leukaemia/lymphoma.
(13 Nov 1997)
t-lymphocyte A white blood cell made in the thymus gland, a lymphoid structure in the upper chest. T lymphocytes are also called T-cells. (the t in T-cell stands for thymus). These cells coordinate the immune system by secreting lymphokine hormones. There are 3 fundamentally different types of t lymphocytes : helper, killer, and suppressor.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • nonstandard analysis
    ÃÊÁØÇؼ®
  • philosphical analysis
    öÇÐÀû ºÐ¼®
  • pollen analysis
    ²É°¡·ç ºÐ¼®;È­ºÐÇÐ
  • qualitative analysis
    Á¤¼º ºÐ¼®
  • quantitative analysis
    Á¤·® ºÐ¼®
  • systems analysis
    (´É·ü,Á¤¹Ðµµ¸¦ ³ôÀ̱â À§ÇÑ) ½Ã½ºÅÛ ºÐ¼®
  • ultimate analysis
    ¿ø¼Ò ºÐ¼®
  • ultimate analysis
    ¿ø¼Ò ºÐ¼®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á